Inspyr Therapeutics (NSPX) Stock Price, News & Analysis

Company Overview

Inspyr Therapeutics, Inc. is a pharmaceutical company, which engages in the research and development of novel therapeutics for the treatment of cancer. Its product pipeline includes Mipsagargin, a dual A2A/A2B antagonist, an A2A antagonist, an A2B antagonist, and an A2A agonist. The company was founded by Craig A. Dionne, John T. Issacs, and Samuel R. Denmeade on November 21, 2003 and is headquartered in Westlake Village, CA.

Key Stats

• Today's Range: $0.0026 to $0.0034
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.07
• Volume: 29.64 million shs
• Average Volume: 13.19 million shs
• Market Capitalization: $1.47 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NSPX Stock Analysis - Frequently Asked Questions

How have NSPX shares performed this year?

Inspyr Therapeutics' stock was trading at $0.0027 at the start of the year. Since then, NSPX stock has increased by 0.0% and is now trading at $0.0027.
View the best growth stocks for 2024 here.

How were Inspyr Therapeutics' earnings last quarter?

Inspyr Therapeutics, Inc. (OTCMKTS:NSPX) released its quarterly earnings data on Monday, August, 14th. The company reported ($26.25) EPS for the quarter.

When did Inspyr Therapeutics' stock split?

Inspyr Therapeutics shares reverse split on Tuesday, October 12th 2021. The 1-75 reverse split was announced on Tuesday, October 12th 2021. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 12th 2021. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Inspyr Therapeutics?

Shares of NSPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Inspyr Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Inspyr Therapeutics investors own include Stem (STEM), Hon Hai Precision Industry (HNHPF), iBio (IBIO), Knight-Swift Transportation (KNX), Blink Charging (BLNK), BIO-key International (BKYI) and BIOLASE (BIOL).

Company Calendar

• Last Earnings: 8/14/2017
• Today: 11/04/2024

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:NSPX
• CUSIP: N/A
• CIK: 1421204
• Web: www.genspera.com
• Phone: (818) 597-7552
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-6,300,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -1,354.49%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.09
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.07) per share
• Price / Book: -0.04

Miscellaneous

• Outstanding Shares: 543,152,000
• Free Float: N/A
• Market Cap: $1.47 million
• Optionable: Not Optionable
• Beta: -17.33